MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-24-1478

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2025

Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.

Lee Sylvia M, Hamid Omid, Jotte Robert, Zakharia Yousef, Medina Theresa, Gillespie-Twardy Amanda, Mehmi Inderjit, Chandra Sunandana, Watson Graham, Ward Patrick, Chaney Marya, Lu Hailing, Berndt Jason, O'Connor Brian P, Rathi Kapil, Shaikh Eeman, Cowey Charles Lance

СтатьяКлиническое исследование II фазыПеревод пока не подготовлен

Аннотация

PURPOSE: Brentuximab vedotin (BV) is hypothesized to selectively deplete T regulatory cells that express CD30 and resensitize tumors to anti-PD-1 therapy. This study evaluated responses to BV + pembrolizumab after PD-1 therapy and explored corresponding biomarkers.

PATIENTS AND

METHODS

A total of 55 patients with metastatic non-small cell lung cancer and 58 patients with metastatic cutaneous melanoma received ≥1 dose of BV + pembrolizumab. Patients had received a median of 2.0 prior lines of systemic therapies (range, 1-7). The primary endpoint was confirmed objective response rate (ORR). Exploratory endpoints included overall survival (OS) and biomarker analysis in blood and tumor.

RESULTS

For the secondary refractory metastatic non-small cell lung cancer cohort (RECIST v1.1), the ORR was 14%, median progression-free survival (PFS) was 5.85 months, and median OS was 14.4 months. For the secondary refractory metastatic cutaneous melanoma cohort (immune RECIST), the ORR was 24%, median PFS was 4.44 months, and median OS was 21.9 months. Overall, the median duration of OS follow-up was 17.2 months (95% confidence interval, 14.62-22.87). No new safety signals were identified. No treatment-related grade 5 toxicity was seen. Longitudinal immune phenotyping in peripheral blood demonstrated a transient decrease in T regulatory cells. Paired tumor biopsies from baseline and cycle 3 day 1 showed a trend of increased CD8 T-cell infiltration, especially in responding patients.

CONCLUSIONS

BV + pembrolizumab in solid tumor malignancies resulted in clinically meaningful, durable responses with encouraging OS and PFS rates supportive of the immunomodulatory activity of this combination. Stronger antitumor activity was observed in secondary refractory cohorts. The safety profile of this combination was consistent with the individual drug risk profiles.

Для цитирования: Lee Sylvia M, Hamid Omid, Jotte Robert, Zakharia Yousef, Medina Theresa, Gillespie-Twardy Amanda, Mehmi Inderjit, Chandra Sunandana, Watson Graham, Ward Patrick, Chaney Marya, Lu Hailing, Berndt Jason, O'Connor Brian P, Rathi Kapil, Shaikh Eeman, Cowey Charles Lance. Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. DOI: 10.1158/1078-0432.ccr-24-1478.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.